Browse Articles
Discover research articles across all indexed journals
A phase 2 study of amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) in metastatic pancreatic cancer.
TPS790 Background: Patients with advanced pancreatic adenocarcinoma (PDC) that progresses after first-line therapy face limited treatment options. Despite advances in systemic therapy, the prognosis for PDC is dismal, with a five-year overall survival (OS) of about 5% . Due to the high morbidity of this disease, there is a critical need for innovative treatments to improve patient outcomes. TheraBionic P1, a hand-held device, delivers tumor specific radio frequencies via a spoon-shaped antenna placed on the patient's tongue. The FDA and EMA have confirmed the safety of the device for amplitude-modulated electromagnetic field (AM-EMF) therapy. Improved efficacy outcomes were reported with AM RF EMF in other solid organ tumors including pancreatic cancer in preliminary studies. Preclinical and clinical evidence suggests that AM-EMF can inhibit tumor growth and was recently approved for use in hepatocellular cancer. The safety and clinical activity observed with AM RF EMF, paired with the unmet medical need for additional effective therapies in pancreatic cancer, provided a strong rationale for further clinical investigation. This protocol evaluates the efficacy and tolerability of AM RF EMF in combination with standard of care frontline therapy, gemcitabine and nab-paclitaxel for metastatic PDC. Methods: This is an ongoing, single-center, Phase II, non-randomized study using a Simon two-stage minimax design to assess the efficacy of AM-EMF in combination with gemcitabine/nab-paclitaxel as a first-line treatment in metastatic pancreatic cancer. Gemcitabine and nab-paclitaxel are administered per standard care. AM RF EMF are delivered to patients with a spoon-shaped applicator placed on the tongue three daily 60-minute treatments. Patients will be assessed for response every 8 weeks. Treatment is continued until progression or toxicity. The primary objective of this study is to evaluate the efficacy of the combination of nab-paclitaxel, gemcitabine, and AM RF EMF in improving 6-month overall survival rates in patients with metastatic PDC. Secondary objectives evaluate the safety, tolerability, profession free survival, objective response rate and disease control rate. Exploratory objectives evaluate change in CA19-9 and quality of life using FACT-General (FACT-G) and determine any possible correlation with clinical outcomes. Key eligibility includes treatment-naïve, histologically confirmed metastatic PC, age eighteen years old or greater, ECOG 0-1, and optimal organ function. Clinical trial information: NCT05776524 .
Costs of generic vs. branded nab-paclitaxel (nP) during first-line (1L) treatment of metastatic pancreatic adenocarcinoma (mPDAC) with gemcitabine + nab-paclitaxel (GnP) in a real-world commercial database.
694 Background: In 2013, the FDA approved GnP for 1L treatment of mPDAC. The total cost of care (TCoC) to payers during treatment is driven by the cost of nP, which first faced competition from generics in April 2022. We examined cost per generic vs. branded nP claim and cost per patient (pt) before and after generic entry. Methods: This retrospective observational study utilized Optum Market Clarity claims + EHR data. Inclusion criteria were: adult pts diagnosed with mPDAC between January 1, 2015 and May 31, 2023; initiated 1L GnP (index date) -14 to +90 days from diagnosis; 6 months pre-index enrollment. Claims were grouped into branded vs. generic based on NDC. For per-pt-per-month (PPPM) analyses, pts were required to have ≥30 days post-index enrollment and no nP claims missing NDCs. Pts were grouped into 1) branded pts with all nP claims for the branded NDC, and 2) generic pts with all claims for generic NDCs. TCoC, inpatient, outpatient, and chemotherapy drug cost to payers were calculated. The full study period and the period of generic entry beginning April 1, 2022 were examined. Results: Costs for branded vs. generic nP claims and GnP pts for 1L treatment initiated April 1, 2022 and after are shown (Table). The mean cost of generic claims was affected by outliers and was more than twice that of branded. The median nP claim cost, less affected by outliers, was still $2,408 greater for generic vs. branded. Costs for branded nP claims were similar before and after generic entry (not shown). 20 1L GnP pts had only branded nP claims, 24 had only generic, and 156 had mixed or were missing ≥1 NDC. PPPM mean TCoC was approximately twice as high for generic vs. branded. Medians were more similar, with generic median $2,037 higher vs. branded. Differences were driven by drug cost; other inpatient and outpatient costs were similar between the two groups (not shown). Costs of branded GnP pts before and after generic entry were similar (not shown). Conclusions: Publicly available prices for branded nP are $1,673 vs. $1,460 for generic per 100mg. In real-world data, we found generic nP costs per claim and PPPM tended to be higher than branded. While GnP is accepted by payers and clinicians as a standard 1L regimen for mPDAC, its real-world drug cost is at the level of branded therapy, despite generic availability. Future research should evaluate this finding as more post-generic-entry data becomes available. Branded vs generic costs. Statistic Branded Generic Claims N 343 308 Cost per claim Mean (SD) 4,721 (2,197) 11,761 (40,559) Median (IQR) 3,482 (2,945–6,583) 5,890 (3,482–6,964) Patients N 20 24 TCoC, PPPM Mean (SD) 25,410 (9,531) 52,129 (121,166) Median (IQR) 22,276 (17,911–32,180) 24,313 (17,231–36,774) GnP drug cost PPPM Mean (SD) 11,056 (4,334) 35,910 (118,205) Median (IQR) 10,162 (7,658–13,508) 10,554 (7,162–16,797)
Ethnic and socioeconomic disparities in cancer-free and all-cause survival in cholangiocarcinoma patients under 60: A population-based study.
527 Background: Cholangiocarcinoma in individuals under 60 years of age is rare, and survival outcomes can vary based on ethnic and socioeconomic factors. While previous studies have examined these disparities in other cancers, little is known about their impact on cancer-free and all-cause survival in younger cholangiocarcinoma patients. This study investigates the role of race and income in survival outcomes for this population. Methods: Data for individuals under 60 diagnosed with cholangiocarcinoma were extracted from the Surveillance, Epidemiology, and End Results (SEER) 22 registry. Kaplan-Meier curves were constructed to assess overall and cancer-free survival. Median survival times were calculated for each racial and income group, and log-rank tests were used to compare survival differences across the groups. Results: A total of 11,214 individuals under 60 years of age diagnosed with cholangiocarcinoma were included. Median all-cause survival was 12.0 months for Asian patients, 11.0 months for White patients, and 9.0 months for both Black and Hispanic patients. Significant differences were observed between Asian vs White (p < 0.005), Asian vs Black (p < 0.005), Asian vs Hispanic (p < 0.005), White vs Black (p < 0.005), and White vs Hispanic (p < 0.005), with no significant difference between Black and Hispanic patients (p = 0.859). For cancer-free survival, the median was 13.0 months for Asians, 12.0 months for Whites, 11.0 months for Blacks, and 10.0 months for Hispanics, with significant differences between Asian vs Black (p < 0.005), Asian vs Hispanic (p < 0.005), and White vs Black (p = 0.017). The difference between Asian vs White was not statistically significant (p = 0.052), and no significant difference was observed between White vs Hispanic (p = 0.418) or Black vs Hispanic (p = 0.418). By income, patients with an income >$75,000 had significantly longer all-cause survival (12.0 months vs 9.0 months, p < 0.005) and cancer-free survival (13.0 months vs 11.0 months, p < 0.005) compared to those with an income of $0-$75,000. Conclusions: Significant disparities in cancer-free and all-cause survival were found based on ethnicity and income. Asian and White patients had longer survival compared to Black and Hispanic patients, and higher-income patients experienced better outcomes. These findings highlight the need for targeted efforts to address healthcare inequalities in cholangiocarcinoma care.
Analysis of anxiety and pain in patients undergoing immediate sequential bilateral cataract surgery or unilateral cataract surgery
Genomic landscape study of esophago-gastric adenocarcinoma (EGAC) in young patients under the age of 30 years.
480 Background: Despite recent advances in treatment of EGAC, prognosis continues to be poor with reported 5-year survival of less than 30%. EGAC is more frequently diagnosed at an old age with the median age at diagnosis around 65 years. However, approximately 10% of EGAC are diagnosed at a younger age of less than 50 years and those patients present with more advanced stages resulting in worse prognosis. Our study investigated the genomic landscape of EGAC diagnosed under the age of 30 years to better understand the characteristics of EGAC occurring in very young population. Methods: 8,001 cases of clinically advanced EGAC who underwent comprehensive genomic profiling (CGP) from 2012 to 2024 were included in the study. Patients aged less than 30 years were classified as ‘EGAC-young’ and patients aged 50 and older were classified as ‘EGAC-old’. All classes of genomic alterations (GA), microsatellite instability high (MSI-high) status, tumor mutation burden (TMB), genomic ancestry, genomic signature, and homologous recombination defect signature (HRDSig) were determined from the sequencing data. PD-L1 was measured by IHC using the Dako 22C3 tumor proportional score (TPS) system. Comparisons utilized the Fisher Exact method with the Benjamini-Hochberg adjustment to reduce the false discovery rate. Results: Out of 8,001 cases, 7389 (92.4%) were classified as ‘EGAC-old’ and 26 (0.3%) as ‘EGAC-young’. Both groups had a higher frequency of male patients but there was no significant difference between the two groups (86.4% vs 76.9%; NS). Median GA per tumor was 6 in both groups. The ‘EGAC-old’ featured a significantly higher frequency of EUR ancestry (92.0% vs 73.1%; P=0.026). There were no significant differences in clinically important GA between both groups, including similar ERBB2 GA (21.2% vs 30.8%; NS) and FGFR3 GA (1.2% vs 7.7%; NS). There was a trend of more frequent GA of AKT2, CCNE1, and KEAP1 noted in ‘EGAC-young’ (0.9% vs 11.5%, 8.5% vs 26.9%, 1.3% vs 11.5%, respectively; P=0.071). MSI-high status was 3.1% in the ‘EGAC-old’ but not detected in the ‘EGAC-young’ (NS). The median TMB was higher in the ‘EGAC-old’ vs ‘EGAC young’ (3.8 mutations/Mb vs 1.9 mutations/Mb; P=.003). The frequencies of a positive HRDSig were similar in both groups (5.6% vs 8.0%; NS). There were no significant differences in COSMIC trinucleotide signatures. PD-L1 expression was identified in greater than 20% of the ‘EGAC-old’ but was not measured in the ‘EGAC-young’. Conclusions: Clinically advanced EGAC in young patients under the age of 30 years features a genomic landscape that differs from EGAC identified in older patients, including lower TMB and a trend of increased GA frequency of genes related to poor prognosis in other types of cancer. Further studies are warranted to utilize CGP findings in identifying potential implications for treatment and prognostication in these rare cases of EGAC occurring in very young patients.
The safety and short-term efficacy of induction DCF plus nivolumab therapy in patients with unresectable locally advanced esophageal squamous cell carcinoma.
425 Background: Definitive chemoradiotherapy (dCRT) is the standard treatment for unresectable locally advanced esophageal squamous cell carcinoma (LA-ESCC) based on the results of the JCOG 0303 study. However, the prognosis in this population remains poor with a median overall survival (OS) of 13.1 months, and fistula formation was reported in about 20% of patients who received dCRT. In such a circumstance, a more effective and safer treatment strategy, such as induction chemotherapy followed by conversion surgery or dCRT, was developed. A phase II study of induction chemotherapy consisting of docetaxel (DTX), cisplatin (CDDP), and 5-fluorouracil (5-FU) (DCF) therapy (IC-DCF) showed a conversion rate of 37.5%, promising efficacy with a median OS of 33.8 months and a fistula formation rate of 4.2%. Therefore, we evaluated whether adding nivolumab to IC-DCF (IC-DCF+Nivo) could improve clinical outcomes. Methods: We retrospectively reviewed the medical records of patients with unresectable LA-ESCC who received IC-DCF+Nivo between Nov 2023 and Aug 2024. IC-DCF+Nivo (DTX 70mg/m2 day1, CDDP 70mg/m2 day1, 5-FU 750mg/m2 day1-5, Nivo 360 mg/body day1, every 3 weeks) was administered for 3 courses. We administered prophylactic levofloxacin from day 5 to day 15 during each cycle, and used granulocyte colony-stimulating factor (G-CSF) as a treatment. We evaluated adverse events according to the CTCAE ver5.0 during induction chemotherapy as safety, and objective response rate (ORR) of IC-DCF+Nivo according to the RECIST version 1.1., conversion surgery rate, complete resection (R0) rate, pathological complete response (pCR) rate and clinical CR (cCR) rate after dCRT as efficacy. Results: The median follow-up period was 5.5 months. We identified 23 eligible LA-ESCC patients, median age (range): 65 (44-76), 83% male, PS 0/1: 57%/44%, T status T3/T4b 44%/57%, clinical stage III/IVA/IVB 22%/57%/22%. Seven patients (30%) had supraclavicular lymph node metastases, and the most common unresectable factors were tracheal invasion (52%), bronchial invasion (22%) and aortic invasion (13%) of primary tumor or metastatic lymph nodes. Eighteen patients (78%) completed the 3 courses of IC-DCF+Nivo. The frequent grade 3-4 hematological adverse events were neutropenia (13/23, 57%) and anemia (3/23, 13%), and 1 patient (4.3%) had grade 3 diarrhea as non-hematological toxicity. Febrile neutropenia occurred in 3 patients (13%), and G-CSF was used in 7 patients (30%). One patient (4.3%) experienced primary tumor perforation. The ORR after 3 cycles of induction chemotherapy was 53%. Fourteen patients (61%) achieved resectability, and 10 patients (44%) underwent surgery. R0 resection rate was 90% (9/10), and the pCR rate was 20% (1/10). No one achieved cCR in dCRT. Conclusions: Induction DCF plus nivolumab therapy showed well-tolerated and well conversion rate.
Quantitative amplification ratio for established and emerging biomarkers in gastroesophageal (GE) cancer.
470 Background: Gene copy number (CN) amplifications (amps) and/or protein overexpression in ERBB2 , EGFR , FGFR2 , and MET represent established and emerging clinical targets in GE. Various methodologies are used to report gene amp or overexpression with some data suggesting FISH ratio may predict therapy response. Quantitative methods for NGS CN and relationship to ISH/IHC remains largely unresolved. We studied the landscape of targetable CN amps in GE to understand correlations of quantitative CN amp ratio and outcomes. Methods: GE tissue (N = 20,468) and liquid (N = 1,760) samples underwent NGS-based comprehensive genomic profiling (CGP). A genome-wide CN model for each sample was generated, segmented, and combined with variant allele frequencies of heterozygous SNPs to estimate the sample purity, ploidy, and CN for each segment. Genes were considered amplified at CN ≥ ploidy + 3 for ERBB2 and + 4 for other genes. Sub-analysis using amp ratio (ratio of the gene CN to the sample ploidy) ≥ 3 was performed. ctDNA tumor fraction (TF) was quantified using a composite algorithm (PMID: 38990098). The Flatiron Health-Foundation Medicine clinico genomic database, a nationwide (US-based) de-identified EHR-derived database linked to CGP data, was queried to assess external HER2 FISH or IHC and describe real-world (rw) progression-free survival (rwPFS) and overall survival (rwOS) of GE patients (pts) with ERBB2 amp on trastuzumab-based regimens. Results: ≥1 gene amps were detected in 15,341 (75%) GE tissue cases, and in 67% of cases using an amp ratio ≥3 threshold. The rates of amps in current clinical targets using each threshold were ERBB2 : 17%/12%, KRAS : 13%/12%, EGFR: 8.7%/7.2%, MET: 5.2%/4.0% , FGFR2: 3.1%/2.7% of tissue samples. The median amp ratio and percent of amps with ratio ≥ 3 were ERBB2 : 7.1/73%, KRAS : 14/92%, EGFR : 13/82%, MET : 6.3/76%, and FGFR2 : 29/88%. Amp ratio ≥ 3 was associated with focal amplicons vs amp ratio < 3 (median amplicon size 0.95 vs. 3.8 Mbp, p < 0.001). Of 1,382 pts with HER2 NGS and IHC results, concordance with IHC3+ was 68% and increasing ERBB2 amp ratio was associated with IHC 3+ status. Of 604 pts with HER2 NGS and FISH, concordance was 80% (118 positive, 366 negative). Higher ERBB2 amp ratio was also associated with longer rwOS and rwPFS as a continuous variable on first-line trastuzumab-based regimens. ≥1 gene amps were detected in 597 (34%) liquid samples (median TF 18%) and 32% with the amp ratio ≥3 threshold, increasing to 79% and 73% with TF ≥ 20% (n=355). Conclusions: Gene amps are common established or emerging GE targets and ERBB2 amp ratio is associated with outcomes for pts on trastuzumab-based regimens. Amp detection in liquid correlates with higher TF and amp ratio. As the number of therapies targeting gene amps and overexpression grows, quantification of the degree of amplification and harmonization across methodologies may be an important tool to select pts for optimal outcomes.
Exploring the feasibility and clinical impact of ultrasound microvascular flow imaging in detecting brain injury in hyperbilirubinemia neonates
Development and validation of a deep learning–based pathomics signature for prognosis and chemotherapy benefits in colorectal cancer: A retrospective multicenter cohort study.
298 Background: The current TNM staging system fails to provide adequate information for prognosis and adjuvant chemotherapy benefits in colorectal cancer (CRC). Pathomics, an emerging field, shows promise in improving prognosis estimation and decision-making. In this study, we developed and validated a pathomics signature (PS CRC ) that directly analyzes hematoxylin and eosin–stained slides using deep learning to predict outcomes. Methods: A total of 883 whole slide images from two cohorts, Harbin Medical University Cancer Hospital and The Cancer Genome Atlas (TCGA), were retrospectively analyzed. An interpretable, multi-instance deep learning model was proposed to establish the PS CRC . Shapley additive explanations were employed to interpret the model's decisions, and gradient-weighted class activation mapping was applied to visualise the pathological phenotypes of the PS CRC . The transcriptomics data from TCGA cohort was used to explore the potential pathogenesis underlying the PS CRC . Results: The PS CRC was identified as an independent prognostic factor associated with both overall survival and disease-free survival. Incorporating the PS CRC into the TNM stage model resulted in a significant improvement in prognosis estimation, as evidenced by a notable increase in net reclassification improvement and integrated discrimination improvement. Moreover, among stage II and III CRC patients with low levels of PS CRC , satisfactory benefits from chemotherapy were observed. Notably, the main underlying features of PS CRC include tumor cell infiltration, adipocyte accumulation, fibrous tissue deposition, and stromal infiltration. Transcriptome analysis further support the relevance of PS CRC to tumor progression and immune suppression. Conclusions: Our finds highlight the significant potential of histopathology images-based deep learning in predicting prognosis and assess therapeutic response of CRC. The PS CRC could serve as an effective tool in clinical decision for CRC management, providing insights into the underlying pathogenic mechanisms. However, prospective studies are still necessary for further validation.
Assessment of clinical value and barriers to use of new investigational targeted agents in the community setting: A study of claudin 18.2 and zolbetuximab.
500 Background: Rapid integration of novel agents in clinical practice can be lifesaving. However, community-based practices may experience extended adoption times, due to practical barriers. REFLECT was developed to assess new drug implementation in the community setting. Methods: REFLECT consists of a 20-minute prerecorded presentation, followed by a data-collection event for community oncologists. It was developed to evaluate and assess challenges of implementing novel targeted agents in the community practice setting. In this pilot study, awareness of zolbetuximab (zolbe), a potential first-in-class claudin 18.2 (CLDN18.2) monoclonal antibody and companion diagnostic, was assessed. Between April and August 2024, 53 data-collection events were held representing 26 states across the US. Data from 492 oncologists were recorded and analyzed. Results: Nearly half the community oncologists (47%) were not familiar with CLDN18.2 as a therapeutic target in gastric/gastroesophageal junction (G/GEJ) cancer. Awareness of zolbe data was low among community oncologists; 79% indicated they had not seen the results from the phase 3 studies. However, 96% of oncologists reported the data will at least moderately impact their treatment of CLDN18.2+ patients with metastatic (m)G/GEJ cancer. Only 40% of oncologists reported having access to CLDN18.2 testing. Uncertainty regarding availability of CLDN18.2 testing was high among oncologists in the Central US (52%), representing a significant awareness gap for CLDN18.2 testing. Opinions were divided regarding the treatment approach for CLDN18.2+, immunosensitive patients (Table). In a HER2–, CLDN18.2+ patient with mG/GEJ cancer and a combined positive score (CPS) of 10; 58.1% would recommend first-line chemotherapy (chemo) plus immunotherapy (IO) and 40.4% would recommend chemo plus zolbe. Conclusions: First-in-class targeted agents often encounter additional challenges and knowledge gaps regarding adoption in the community practice setting, particularly associated with molecular testing. Timely education on patient identification and correct utilization may accelerate adoption of new regimens, and potentially save lives. Data-sharing and -collection platforms including REFLECT can be instrumental in the identification of challenges associated with widespread and rapid implementation of novel agents in the community oncology setting. What treatment approach would you recommend in a patient with the following characteristics, if all treatments were available? mGEJ adenocarcinoma, HER2– disease, CLDN18.2+ staining in >75% of tumor cells, CPS 10. Treatment Total: N = 492% (n) Chemo mFOLFOX6 1.0 (5) CAPOX 0 (0) Chemo + IO mFOLFOX6 + IO 52.8 (260) CAPOX + IO 5.3 (26) Chemo + zolbe mFOLFOX6 + zolbe 33.9 (167) CAPOX + zolbe 6.5 (32) Other 0.4 (2)
Efficacy and safety of cabozantinib for advanced gastrointestinal (GI) neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of the phase 3 CABINET trial (Alliance A021602).
666 Background: In the phase 3 CABINET trial (NCT03375320), cabozantinib (CABO) significantly prolonged median progression-free survival (PFS) compared to placebo (PB) in patients with advanced, previously treated, progressive extrapancreatic NET (epNET) [HR 0.38 (95% CI, 0.25-0.59, P<0.0001)] and pancreatic NET (pNET) [HR 0.23 (95% CI, 0.12-0.42, P<0.0001)] (Chan et al., NEJM, 2024). In this analysis, we focus on outcomes of patients with epNET arising in the GI tract. Methods: Patients with locally advanced or metastatic epNET or pNET were randomized 2:1 in separate cohorts to receive CABO 60 mg daily vs PB. The epNET cohort included patients with tumors arising in the GI tract (not including pancreas), lung, unknown primary, and other rare primary sites. In this subgroup analysis of the epNET cohort, patients with GI NET were included. Eligibility included progression by RECIST within 12 months (mo) prior to registration, ≥ 1 prior systemic therapy. Primary endpoint: PFS by blinded independent central review (BICR). Secondary endpoints: objective response rate, overall survival, safety. Results: 116 of the 203 patients in the epNET cohort had GI NET (CABO, n=70; PB, n=46). Median age was 66 yrs; females: 46%; G1/G2/G3/unknown grade: 35%/57%/6%/2%. ECOG performance status: 0/1-2: 43%/57%. White race: 86%. The most common primary tumor locations were ileum/cecum (54%), small intestine with location not specified (20%); non-cecum colon or rectum (11%), stomach (4%); duodenum (3%); jejunum and nonspecified midgut site (3% each). Prior systemic therapies included somatostatin analogs (SSA) (100%), everolimus (59%); Lu-177 dotatate (77%); temozolomide +/- capecitabine (16%). In patients with GI NET, CABO was associated with improved PFS by BICR compared to PB (stratified HR, 0.50; 95% CI: 0.28-0.88, 1-sided stratified log-rank P=0.007). Median PFS with cabozantinib was 8.5 mo (95% CI, 6.0-16.7) compared to 5.6 mo (95% CI, 3.9-11.0) with PB. CABO demonstrated potential benefit in patients with midgut GI NET and across clinical factors including grade, functional status related to hormone secretion, concurrent SSA use, and prior therapy with Lu-177 dotatate or everolimus. The most frequent grade 3/4 adverse events attributed to therapy with CABO included hypertension (19%), diarrhea (13%), fatigue (10%). Conclusions: CABO is associated with improvement in PFS compared to PB in patients with advanced GI NET. Potential benefit was observed across clinical factors including grade, functional status, concurrent SSA, and prior treatment. The safety profile for CABO in patients with GI NET is consistent with that previously reported. Support: U10CA180821, U10CA180882; U10CA180820 (ECOG-ACRIN), U10CA180868 (NRG Oncology), U10CA180888 (SWOG); Exelixis; https://acknowledgments.alliancefound.org . Clinical trial information: NCT03375320 .
AI-based prediction of androgen receptor expression and its prognostic significance in prostate cancer
Size‐Dependent Cascade Enhancement of T <sub>1</sub> ‐T <sub>2</sub> Dual‐Modal MRI in Tumors
Abstract Currently, there is no conclusive evidence indicating that in situ self‐assembled Gd nanostructures of varying sizes demonstrate distinct T 1 and T 2 signal enhancement capabilities. Furthermore, it remains uncertain whether size adjustment can effectively achieve enhanced T 1 ‐T 2 dual‐modal MRI. To address these uncertainties, a two‐step in situ self‐assembly strategy is developed. This approach began with a small‐sized nanoprobe, Gd‐TCO‐P, with a hydrodynamic diameter (dH) of 16 ± 3 nm. This nanoprobe underwent alkaline phosphatase (ALP) cleavage and self‐assembled intracellularly into short nanofibers termed Gd‐NFs (dH: 200 ± 51 nm). The subsequent introduction of tetrazine‐tetrazine crosslinked these Gd‐NFs, leading to the formation of larger two‐stage dendritic nanofibers known as Gd‐TS‐NFs (dH: 4371 ± 236 nm). This process achieves size‐dependent enhancement of both T 1 and T 2 signals, which is validated through both in vitro and in vivo experiments, enabling precise long‐term imaging of ALP‐overexpressing tumors. This study not only provides valuable insights into the relationship between the size of in situ formed Gd nanostructures and T 1 /T 2 MRI contrast enhancement, but also suggests a promising strategy for clinical applications of T 1 ‐T 2 dual‐modal MRI.
Can overall survival (OS) benefit be predicted from improvements in progression-free survival (PFS) for previously untreated metastatic colorectal cancer (mCRC)?
222 Background: With improvements in treatment of mCRC, OS maintains its gold standard efficacy measure but takes longer to mature than intermediate endpoints. This study analyzed the association between treatment effects on PFS and OS using aggregate-level data from RCTs in previously untreated mCRC patients. Methods: A systematic literature review identified RCTs in previously untreated mCRC patients published from 2010–2021 reporting hazard ratios on PFS (HR PFS ) and OS (HR OS ). All treatments in comparison to chemotherapy alone or chemotherapy with anti-VEGF (bevacizumab) or anti-EGFR (cetuximab) targeted therapy were considered. Correlation between HR PFS and HR OS was evaluated using bivariate random-effects meta-analysis (BRMA) and weighted linear regression (WLR). Predictive performance of the surrogacy equations from WLR was assessed using leave-one-out cross-validation (LOOCV). Surrogate threshold effects (STE), defined as the minimum PFS benefit that would translate into a statistically significant OS benefit with 95% probability, were also derived to gauge the practical utility of the models. Primary analysis consisted of all included trials. Sensitivity analyses omitted trials that (I) had anti-EGFR medications, (II) had anti-VEGF medications, (III) violated proportional hazards assumptions, and (IV) permitted treatment crossover. Results: In the primary analysis 47 trials were included. The estimated correlation between PFS and OS was 0.67 (95% CI: 0.48–0.80) using BRMA and 0.70 (95% CI: 0.48–0.84) using WLR. The surrogacy equation derived from WLR was log(HR OS ) = −0.03 + 0.56 log(HR PFS ) with a statistically insignificant intercept and significant slope. Estimated STEs corresponding to sample sizes of 200 and 300 patients were 0.55 and 0.62, respectively. Observed HR OS ’s were within their 95% prediction intervals predicted from HR PFS for 93.6% of studies in LOOCV. Sensitivity analyses produced moderate correlations with >90% coverage in LOOCV (Table). Conclusions: Moderate correlations were found between HR PFS and HR OS using both modeling approaches, highlighting the stability of the findings. Cross-validations of surrogacy equations indicated promising predictive value of PFS benefit for OS benefit in previously untreated mCRC. Analysis Set # of Studies Correlation (95% CI) STE LOOCVCoverage Rate BRMA WLR N = 200 N = 300 Sensitivity Analysis I 34 0.75 (0.57, 0.86) 0.78 (0.55, 0.90) 0.55 0.61 94.1% Sensitivity Analysis II 14 0.44 (-0.08, 0.77) 0.62 (-0.05, 0.90) 0.44 0.52 92.9% Sensitivity Analysis III 36 0.61 (0.36, 0.77) 0.59 (0.26, 0.80) 0.46 0.55 94.4% Sensitivity Analysis IV 43 0.68 (0.48, 0.81) 0.67(0.41, 0.83) 0.52 0.60 93.0%
Comparative analysis of racial disparities in social determinants of health among patients with GI cancer in the All of Us dataset.
804 Background: Social Determinants of Health (SDoH) are key factors in understanding disparities in cancer treatment and outcomes. Examining SDoH across racial and ethnic groups helps uncover the mechanisms behind disparities and identify solutions. This study compared SDoH factors between White (non-Hispanic) and Non-White (Asian, African American, Hispanic) patients diagnosed with Gastrointestinal (GI) cancers using a national dataset. Methods: We analyzed data from the All of Us Research Program. Adult patients with GI cancers, identified via ICD-10 and SNOMED codes, who had completed the SoDH surveys were included. Comparative analyses were performed between White and Non-White participants across SDoH constructs, including social/community construct, neighborhood environment, economic stability, and healthcare access using Chi-squared, T-test, and Mann-Whitney U tests as appropriate. Results: Of the 6,620 GI cancer patients identified, 1,831 completed the SDoH survey, of which 13.9% were Non-White. The most common cancers were colon and liver, with pancreatic, stomach, rectal, esophageal, and biliary tract cancers also included. White participants were older than Non-White participants (71.0 vs. 64.2 years, SD = 10.7 and 11.4) and reported higher levels of social cohesion (Mean (SD) = 3.92 (0.70) vs. 3.64 (0.76), p < 0.001) and social support (Mean (SD) = 3.92 (1.00) vs. 3.68 (1.11), p < 0.001). Non-White participants experienced greater perceived discrimination (Mean (SD) = 1.73 (0.80) vs. 1.54 (0.57), p = 0.016) and reported more neighborhood physical disorder (p < 0.001). Food insecurity (23.6% vs. 5.8%, p < 0.001) and housing quality issues (41.8% vs. 21.8%, p < 0.001) were more common among Non-White participants, who also faced more delayed medical care (45.9% vs. 32.5%, p < 0.001). Conclusions: This study highlights racial disparities in SDoH among GI cancer patients. Non-White participants experienced greater economic instability and neighborhood disorder compared to White participants. The All of Us dataset offers valuable data for examining SDoH in this population, though it may not fully represent the broader US population. As the dataset expands, it will provide more opportunities for comparative analyses among cancer patients across racial and demographic groups. Construct White Non-Hispanic (n = 1489) Non-White (n = 255) P-Value Gender: Female, n (%) 827 (55.5) 167 (65.5) p = 0.010 Social Disorder; mean (SD) 2.10 (0.22) 2.17 (0.28) p = 0.002 Perceived Stress; mean (SD) 11.36 (7.12) 12.85 (7.99) p = 0.003 Global Physical Health T-score (SD) 37.16 (1.89) 36.26 (2.08) p < 0.001 Global Mental Health T-score (SD) 38.30 (1.76) 38.22 (1.86) p = 0.520 Food Insecurity; n (%) 170 (5.8) 117 (23.6) p < 0.001 Poor Housing Quality; n (%) 326 (21.8) 127 (41.8) p < 0.001 Delayed Medical Care; n (%) 484 (32.5) 117 (45.9) p < 0.001 Cannot afford specialist; n (%) 47 (4.2) 20 (11.9) p < 0.001
Use of molecular residual disease (MRD) testing with measurement of circulating tumor DNA (ctDNA) post-operatively in stage II colon cancer (SIICC) in the community-based setting.
53 Background: 80% of adult oncology patients (pts) are treated in the community-based setting. Data on the implementation of emerging technologies such as ctDNA testing is scant in this population. Use of adjuvant chemotherapy in SIICC pts historically was based on clinical/pathological risk factors however new data presented in mid 2022 utilizes the presence or absence of ctDNA 6-8 weeks post operatively to help risk stratify pts. The absence of ctDNA predicts a high chance of disease-free survival. Use of ctDNA was incorporated into the NCCN Colon Cancer guidelines as of 2023. In a private practice setting, we retrospectively looked at the use of ctDNA assay for adjuvant chemotherapy decision-making in SIICC pts. Methods: We conducted a retrospective study to quantify ctDNA testing frequency in SIICC pts in our community based oncology practice. The historical cohort was comprised of pts diagnosed prior to the NCCN guideline inclusion of ctDNA; the current cohort included pts diagnosed after the NCCN guideline change. For all pts, we reviewed clinicopathologic risk factors deemed to be high risk (positive margin, < 12 LN removed, tumor budding, lymphovascular invasion, poorly differentiated features; perforation or obstruction) and used this for stratification. Low-risk pts had no high risk features. Medical record data (office notes, pathology, molecular testing) was evaluated to determine ctDNA results including timing and use of adjuvant chemotherapy. Primary endpoint was the percent (%) of current pts who were low-risk with ctDNA testing sent compared to historical control. Secondary endpoint was the % of ctDNA testing sent within 8 weeks of curative surgery in both cohorts. Results: In a private practice setting, we identified low-risk SIICC pts spanning a 36-month period and categorized them into two groups: the historic cohort (A) pts were diagnosed between July 2021-Dec 2022, and the active cohort (B) pts were diagnosed between Jan 2023-July 2024. 26 pts were identified in cohort A and 36 pts were identified in cohort B to have SIICC. Out of 26 pts in cohort A, we identified 13 low risk SIICC pts; for cohort B, out of 36 pts, we identified 25 low-risk SIICC pts. The percentage of pts in each group that had ctDNA testing sent was 79.6% (10/13 pts) in cohort A and 92% (23/25 pts) in cohort B. In cohort A, 80% (8/10 pts) and in cohort B, 90.9% (20/22 pts) had ctDNA sent within 8 weeks of surgery. Conclusions: Incorporation of ctDNA testing in low-risk SIICC pts in a community-based setting occurred quickly. As ctDNA testing was implemented into practice, a majority of pts had the testing sent in the appropriate time frame. Future best practices, especially in the community, should incorporate tumor specific clinician oversight with use of updated pathways to ensure any recent changes to standard of care are followed.
Optimizing AI models to predict esophageal squamous cell carcinoma risk by incorporating small datasets of soft palate images
Automated radiomics model for preoperative pancreatic neuroendocrine tumor grade prediction.
655 Background: Pancreatic neuroendocrine tumors (PNETs) have varying biologic behavior based on factors including tumor grade. Many prognostic factors can only be determined post-pancreatectomy; thus, are unable to guide clinical decision making preoperatively. This is particularly relevant in small, non-functional (NF)-PNETs. Imaging analysis with radiomics may be able to elucidate biologic data such as tumor grade, without the need for tissue sampling. Our study aims to create an automatic pipeline from segmentation to radiomics-signature building to preoperatively predict tumor grade. Methods: Patients that underwent resection between 2003-21 with adequate preoperative arterial phase CT scans were divided into training and validation cohorts. In the training cohort, the pancreas and tumor region were manually segmented and used to train an auto-segmentation model. The validation cohort then underwent automatic segmentation. A total of 255 radiomics features were extracted from the tumor region. Correlated features were removed, and the minimum redundancy maximum relevance (mRMR) method was used to select the final feature set. These features were used to train a Support Vector Machine (SVM)-based classifier through the training cohort to predict grade, which was dichotomized into grade I versus II/III. The radiomic based prediction model was then evaluated in the automatically segmented validation cohort. Results: A total of 186 patients were identified and divided into training (n = 140) and validation (n = 46) cohorts. Median age was 57 (27, 85) and 52% were male. 113 (62%) and 70 (38%) patients were grades I and II/III, respectively. Median tumor size was 24 mm (6, 200) and 43 (26%) patients had positive nodal disease. The auto-segmentation model was able to accurately segment the tumor region in 33 (72%) patients of the validation cohort. In the training cohort (n = 140), the radiomics-signature produced an area under the curve (AUC) of 0.87 (0.81, 0.93). Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were 0.94 (0.9, 0.98), 0.74 (0.66, 0.81), 0.72 (0.65, 0.80) and 0.97 (0.94, 1.00) respectively. In the auto-segmented validation cohort (n = 33), the radiomics model produced an AUC of 0.75 (0.61, 0.90). Sensitivity, specificity, PPV and NPV were 0.88 (0.77, 0.99), 0.62 (0.46, 0.79), 0.71 (0.56, 0.87) and 0.83 (0.71, 0.96), respectively. Conclusions: The proposed auto-segmentation model was able to automatically identify tumor regions with a high degree of accuracy. Similarly, the subsequent radiomics-signature was also able to strongly discern PNET grade. This automatic pipeline bypasses manual segmentation and could help incorporate a radiomics-signature into preoperative clinical decision-making for PNETs.
Expression of Trop2, Nectin-4, and FOLR1 cell surface markers in biliary tract cancers: Is it time to repurpose drugs?
637 Background: Biliary tract cancers (BTC), including gall bladder cancer, intrahepatic and extrahepatic cholangiocarcinoma are aggressive malignancies, with poor prognosis. Despite advances in frontline setting, and in biomarker selected population (IDH1, FGFR2, Her2, BRAF, HRD), there is a dire need to advance therapy in subsequent lines. Methods: We identified BTC patients (pts) at Roswell Park Cancer Center who underwent curative intent surgery between 01/2006-01/2020. After excluding duplicate samples and those with insufficient tissue, we found 78 pts with adequate follow up for analysis. Expression of trophoblast cell surface antigen 2 (Trop2), nectin4, folate receptor alpha (FOLR1) was assessed by immunohistochemistry and correlated with clinical outcomes. H score, a weighted index score that factor in, the % of cells across different intensity was calculated. H scores were classified as negative (0) and positive (>1). Positive H scores were grouped as weak (1-100), intermediate (101-200) and strong (201-300). Descriptive statistics were conducted, and multivariate analyses performed (R studio) to study any correlation between expression of markers and survival outcomes. Results: The median age of our cohort was 67.5 years (range 40-87) with 58% male; 24.4%, 30.8%, 20.5%, 7.7% had stages I, II, III, IV disease. Staging information was missing in 16.7% of pts. Of 73 analyzable samples for Trop2, all were positive for Trop2, with a mean H score of 86, SD of 68.9. 56.4% of patients had a weak H score, 30.8% had an intermediate H score and 6.4% had a strong H score for Trop2. Median overall survival (mOS) among low, intermediate and high expressing group of pts with Trop2 was 48.9 months (m), 23.9 m, and 41.9 m with median Progression Free Survival (mPFS) of 37.8m, 15.3 m, and 37.4 m, respectively. Of 75 analyzable samples for FOLR1 and Nectin4, FOLR1 was expressed in 51.3% with a mean H score of 6.97 (SD 21.9). Nectin4 was expressed in 78.2%, with a mean H score of 13.7 (SD 26.3). Pts with Trop2 expression had a mOS of 39.5 m and a mPFS of 28.7 m. There were no significant differences in mOS (48.9 m vs 33.3 m, p =0.14) and mPFS (37.8 m vs 26.2 m, p =0.35) among patients with positive vs negative FOLR1 respectively. There was no difference in mOS (41.6 m vs 38.3 m, p=0.92) and mPFS (32.8 vs 26.4 m, p-value=0.5) in patients with positive vs negative Nectin4. Multivariate analyses showed that pts with intermediate Trop2 (H score=101-200) had a high risk of death (HR 21.44, CI 2.81-163.4, p= 0.003). Conclusions: Though no difference was seen in clinical outcomes in pts with strong Trop2 expression, FOLR1, and Nectin4 expression, this could be explained by the small sample size. Trop2 is frequently expressed in BTCs and patients with Intermediate Trop2 H score had lower mOS and mPFS, with a higher risk of mortality. This warrants further investigation into potential use of Antibody Drug conjugates against Trop2 in BTC.
Updated results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgery—A single arm, multi-center, phase II clinical trial.
588 Background: High recurrence rate after curative resection significantly compromised the long-term survival of patients with HCC patients (pts). TACE as adjuvant therapy was proved to improve clinical outcomes for pts with high recurrence risk factors after hepatectomy. However, the prognosis of TACE reminded unsatisfactory and controversial. Therefore, this study aimed to identify the efficacy and safety of anlotinib as maintenance adjuvant treatment following inductional TACE in pts with HCC. The preliminary results had been reported in 2024 ASCO GI (Poster 513) and the update results were reported here with longer follow-up duration. Methods: HCC pts with one of the following high risk factors after hepatectomy: ≥5 cm and <10 cm of tumor diameter, tumor number ≥3, tumor microvascular invasion M1 or M2, portal vein tumor thrombus resection (Cheng's classification I/II) were recruited. Eligible pts received cTACE treatment within 1-2 months after hepatectomy, on the 3-5th day after cTACE, oral anlotinib (12mg, qd, d1-d14, q3w) was given until disease recurrence or unacceptable toxicity. The predefined sample size was 30. The primary endpoint was disease free survival (DFS). Secondary endpoints included 1-year DFS rate, time to recurrence and safety. Results: The data cut-off date was April 2024, 29 pts were enrolled and 27 pts received at least once tumor assessment. The median follow-up was 34.1 (IQR, 32.0-40.9) months. Of 27 with assessable efficacy, mDFS was 40.9 (95% CI, 11.4-70.3) months, with 1-, 2-, and 3-year DFS rates of 72.1% (95% CI, 50.2%-85.6%), 63.0% (95% CI, 40.7%-78.9%), and 56.7% (95% CI, 33.6%-74.5%), respectively. 21 of 27 pts (77.8%) experienced treatment-related adverse events (TRAEs). Grade 3 TRAEs occurred in 5 pts (18.5%) included hypertension (7.4%), leukocytopenia (7.4%) and ascites (3.7%), and blood bilirubin increased (3.7%). No grade 4 or 5 TRAEs occurred. Conclusions: Anlotinib combined with TACE as adjuvant therapy in HCC pts at high recurrence risk exhibited encouraging efficacy and tolerable safety profile. And the conclusions needed to be confirmed in large scale clinical trials subsequently. Clinical trial information: NCT04213118 .